Latest News On KFF

Latest California Healthline Stories

KFF Health News' 'What the Health?': A Not-So-Health-y GOP Debate

The first Republican presidential debate of the 2024 cycle took place without front-runner Donald Trump — and with hardly a mention of health issues save for abortion. Meanwhile, in Florida, patients dropped from the Medicaid program are suing the state for not giving them enough notice or a way to contest their being dropped from the program. Margot Sanger-Katz of The New York Times, Joanne Kenen of the Johns Hopkins Bloomberg School of Public Health and Politico, and Victoria Knight of Axios join KFF Health News’ Julie Rovner to discuss these issues and more. Plus, for “extra credit,” the panelists suggest health policy stories they read this week they think you should read, too.

KFF Health News' 'What the Health?': A Year Without Roe

It’s been a year since the Supreme Court overturned Roe v. Wade and, with it, the nationwide right to abortion. The decision in Dobbs v. Jackson Women’s Health Organization set off widespread uncertainty in government and the courts about the legality or illegality of the procedure. But the decision has had other consequences too, including affecting where health professionals choose to locate. In this special episode of KFF Health News’ “What the Health?” Alice Miranda Ollstein of Politico, Shefali Luthra of The 19th, and Sandhya Raman of CQ Roll Call join KFF Health News chief Washington correspondent Julie Rovner to discuss these issues and more. Also this week, Rovner interviews KFF’s Alina Salganicoff about the organization’s research and other work on women’s health policy over the past year.

KFF Health News' 'What the Health?': The Confusing Fate of the Abortion Pill

The legality and availability of the abortion pill mifepristone is in question after a federal judge in Texas canceled the FDA’s approval of the first drug used in the two-drug medication abortion regimen. A 5th Circuit Court of Appeals panel overruled that decision in part, saying the pill should remain available, but only under the onerous restrictions in place before 2016. Meanwhile, another federal judge in Washington state issued a ruling in a separate case that conflicts with the Texas decision, ordering the FDA not to roll back any of its restrictions on the drug. Victoria Knight of Axios, Shefali Luthra of The 19th, and Sarah Karlin-Smith of the Pink Sheet join KFF Health News chief Washington correspondent Julie Rovner to discuss these issues and more.